News & Press

Filter by year:

Presentation at The Lancet Summit on GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis

Geneva, Switzerland, December 20, 2021 – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that its Chief Scientific Officer, Dr. Hervé Perron, unveiled today at the “The Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases” additional results from the preclinical research program in Amyotrophic lateral sclerosis (ALS) developed in partnership with the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH).

GeNeuro receives CHF 6.7 million (EUR 6.4 million) in funding from the Swiss government for the development of temelimab against Long-COVID

Geneva, Switzerland, 13 December 2021, 08:15 CET - GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final Phase II results in multiple sclerosis expected in March 2022, announced today that its development in Long-COVID is one of the four projects selected by the Swiss Federal Office of Public Health (FOPH) and that it will receive in this regard a grant of 6.7 million Swiss francs (€6.4 million) to co-fund a Phase 2 clinical trial to treat patients with long-standing COVID who exhibit severe neurological and psychiatric ("neuropsychiatric") symptoms.

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study

MS Journal, July 9, 2021

Presentation at American Neurological Association Congress Confirms Potential of GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis

Geneva, Switzerland, 18 October, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that the NINDS, part of the U.S. National Institutes of Health (NIH), presented novel pre-clinical results at the American Neurological Association (ANA) annual meeting, October 17-19, confirming in pre-clinical models of ALS the neurotoxic properties of HERV-K ENV, a retroviral envelope protein encoded by a pathogenic member of the HERV-K family of endogenous human retroviruses, and the therapeutic potential of GeNeuro's antibody developed to neutralize HERV-K ENV.

GeNeuro Reports 2021 Half-Year Results and Provides Corporate Update

Geneva, Switzerland, September 29, 2021 at 7:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported its half-year financial results for the period ending June 30, 2021 and provided a corporate update.

GeNeuro and Northwestern University enter into a research collaboration on HERV-W ENV in long-haul COVID

Geneva, Switzerland, September 24, 2021, 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis, announces today that it has entered into a research agreement with Northwestern University to further investigate the relationship between HERV-W ENV (W-ENV) and long-COVID neuropsychiatric syndromes.

GeNeuro announces that a first patient having finished the ProTEct-MS study at the Karolinska Institutet’s Academic Specialist Center has entered the study extension

Geneva, Switzerland, September 21, 2021 – 6:30 pm CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that a first patient having completed its ProTEct-MS study at Karolinska Institutet’s Academic Specialist Center (ASC) in Stockholm, which tests temelimab at monthly doses of 18, 36 and 54 mg/kg in MS patients, has entered the ProTEct-MS extension

GeNeuro: financial information and business update for the second quarter 2021

Geneva, Switzerland, July 23, 2021, 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2021 second quarter cash position and issued a business update.

GeNeuro announces the publication in Multiple Sclerosis of results from CHANGE-MS and ANGEL-MS studies

Geneva, Switzerland, July 15, 2021 – 08:00am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical developing new treatments for neurodegenerative diseases, such as multiple sclerosis (MS), today announced publication in Multiple Sclerosis of the safety and efficacy results from its temelimab CHANGE-MS and ANGEL-MS clinical studies.

GeNeuro: successful €6 million private placement

Geneva, Switzerland,  July 13, 2021 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (“MS”), today announced the successful completion of a €6.0 million capital increase with cancellation of the preferential subscription rights through an international private placement only to certain qualified and institutional investors of 1,730,458 new ordinary bearer shares of GeNeuro with a par value of CHF 0.05 each (the “New Shares” and the "Offering", respectively).


Results 1-10 of 21      Next Page      Last Page